维生素D对老年非裔美国人骨强度的影响:一项随机对照试验
该3年随机对照试验纳入260名≥60岁绝经后非裔美国女性,评估维持血清25(OH)D>30 ng/mL对骨强度的影响。结果显示活性组平均维生素D3剂量3490±1465 IU/天,血清25OHD达46.8±1.2 ng/mL,但股骨颈宽度及CSI、BSI、ISI等骨强度指标与安慰剂组无显著差异(所有p>0.05)。结论认为维持该水平不影响骨强度,不支持超过IOM推荐摄入量的维生素D补充。
要点
- 维持血清25(OH)D>30 ng/mL未改善老年非裔美国女性骨强度指标。
- 活性组平均维生素D3剂量3490±1465 IU/天,血清25OHD为46.8±1.2 ng/mL。
- 股骨颈宽度及CSI、BSI、ISI的组间差异均无统计学意义(p>0.05)。
核心结论
- 维持血清25OHD>30 ng/mL(75 nmol/L)不影响老年非裔美国女性的骨强度。
- 无证据支持该人群为骨强度而摄入超过IOM推荐膳食许可量的维生素D。
研究设计与样本
- 3年随机对照试验,纳入260名≥60岁健康绝经后非裔美国女性,随机分入维生素D3组或安慰剂组。
- 维生素D3剂量调整以维持血清25OHD>30 ng/mL,采用双能X线吸收法测量骨密度、股骨轴长和股骨颈宽度,计算CSI、BSI、ISI。
主要发现
- 参与者平均年龄68.2±4.9岁,两组基线特征相似。
- 活性组平均维生素D3剂量3490±1465 IU/天,血清25OHD平均46.8±1.2 ng/mL,安慰剂组20.7±1.1 ng/mL。
- 血清25OHD与任何复合指数均不相关。
- 两组股骨颈宽度、CSI、BSI、ISI的纵向差异均无统计学意义(所有p>0.05)。
- 任何复合指数均无组×时间交互效应(所有p>0.05)。
关键数值与推荐
- 血清25OHD目标阈值:>30 ng/mL(75 nmol/L)。
- 骨强度复合指数包括压缩强度指数(CSI)、弯曲强度指数(BSI)和冲击强度指数(ISI)。
临床怎么用
- 对老年非裔美国女性,无需为骨强度而将维生素D补充至超过IOM推荐摄入量。
- 维持血清25OHD>30 ng/mL未显示骨强度获益,临床决策应结合现有指南推荐。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: There is controversy over whether African Americans have higher vitamin D requirements than recommended by the Institute of Medicine. We previously reported that maintaining serum 25(OH)D above 30 ng/mL does not prevent age-related bone loss. Herein, we report that bone strength is also unaffected by maintaining this level in this population. INTRODUCTION: The role of vitamin D in bone strength has not been investigated in the African American (AA) population. METHODS: A 3-year randomized controlled trial was designed to examine the effect of vitamin D supplementation on physical performance, bone loss, and bone strength in healthy older AA women. A total of 260 postmenopausal AA women, ages ≥ 60 years were randomized to a vitamin D3 or placebo arm. Vitamin D3 dose was adjusted to maintain serum 25OHD > 30 ng/mL. Bone mineral density, femoral axis length, and femoral neck (FN) width were measured by dual-energy X-ray absorptiometry. Composite indices of FN strength [compression strength index (CSI), bending strength index (BSI), and impact strength index (ISI)] were computed. RESULTS: The mean age of participants was 68.2 ± 4.9 years. Baseline characteristics between groups were similar. The average dose of vitamin D3 was 3490 ± 1465 IU/day in the active group. The mean serum 25OHD was 46.8 ± 1.2 ng/mL versus 20.7 ± 1.1 ng/mL in the active versus placebo group. Serum 25OHD did not correlate with any composite indices. The longitudinal differences observed in FN width, CSI, BSI, and ISI in both groups were not statistically significant (all p values > 0.05). Further, there was no group × time interaction effect for any of the composite indices (all p values > 0.05). CONCLUSION: Maintaining serum 25OHD > 30 ng/mL (75 nmol/L) does not affect bone strength in older AA women. There is no evidence to support vitamin D intake greater than the recommended RDA by the Institute of Medicine in this population for bone strength.
引用
- Dhaliwal R, Islam S, Mikhail M, et al. Effect of vitamin D on bone strength in older African Americans: a randomized controlled trial. Osteoporos Int. 2020. PMID: 31938818. doi:10.1007/s00198-019-05275-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。